British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 4 , Pages 294-297 , June 2009

Bisphosphonate osteonecrosis: a protocol for surgical management

  • George Markose

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 1563 577296; fax: +44 1563 577300.
    • ,
  • Fiona R. Mackenzie

      Affiliations

    • Tel.: +44 1563 577296; fax: +44 1563 577300.
    • ,
  • W.J.R. Currie

      Affiliations

    • Tel.: +44 1563 577293; fax: +44 1563 577300.
    • ,
  • W.S. Hislop

      Affiliations

    • Tel.: +44 1563 577288; fax: +44 1563 577300.

,Accepted 9 January 2009.

References 

  1. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–76.
  2. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83:1930–1935
  3. Hughes DE, Wright KR, Uy HL, Sasaki A, Roneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478–1487
  4. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995;17:137–144
  5. Kapitola J, Zak J, Lacinova Z, Justova V. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res. 2000;49(Suppl. 1):s101–s106
  6. Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res. 1998;47:237–240
  7. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538–6544
  8. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055–1061
  9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117
  10. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surge Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433–441
  11. Freiberger J, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65:1321–1327
  12. Agrillo A, Petrucci MT, Tedaldi M, Murtazza MC, Marino SM, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg. 2006;17:1080–1083
  13. LongobardiG , Boniello R, Gasparini G, Pagano I, Pelo S. Surgical therapy for osteonecrotic lesions of the jaws in patients in therapy with bisphosphonates. J Craniofac Surg. 2007;18:1012–1017
  14. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007;28:158–163

PII: S0266-4356(09)00028-X

doi: 10.1016/j.bjoms.2009.01.007

British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 4 , Pages 294-297 , June 2009

Article Tools

* Image Usage & Resolution